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Gene expression signature analysis <p>A new method for cost-effective high-throughput gene expression signature analysis is described.</p>
Abstract
Genome-wide transcriptional profiling has shown that different biologic states (for instance, disease
and response to pharmacologic manipulation) can be recognized by the expression pattern of
relatively small numbers of genes. However, the lack of a practical and cost-effective technology
for detection of these gene expression 'signatures' in large numbers of samples has severely limited
their exploitation in important medical and pharmaceutical discovery applications. Here, we
describe a solution based on the combination of ligation-mediated amplification with an optically
addressed microsphere and flow cytometric detection system.
Background
Gene expression signatures comprised of tens of genes have
been found to be predictive of disease type and patient
response to therapy, and have been informative in countless
experiments exploring biological mechanism (for example [1-
4]). High-density DNA microarrays therefore represent the
method of choice for unbiased transcriptome analysis and
represent an excellent route to signature discovery. However,
gene expression signatures with diagnostic potential must be
validated in large cohorts of patients, in whom measuring the
entire transcriptome is neither necessary nor desirable. Per-
haps more important is that the ability to describe cellular
states in terms of a gene expression signature raises the pos-
sibility of performing high-throughput, small-molecule
screens using a signature of interest as the read out. However,
for this to be practical one would need to be able to screen
thousands of compounds per day at a cost dramatically below
that of conventional microarrays.
We therefore developed a simple, flexible, cost-effective, and
high-throughput gene expression signature analysis solution
tailored for the measurement of up to 100 transcripts in many
thousands of samples by combining multiplex ligation-medi-
ated amplication [5-7] with the Luminex FlexMAP (Luminex,
Austin, TX, USA) optically addressed and barcoded micro-
sphere and flow cytometric detection system, that we together
refer to as LMF (Figure 1) [8]. Here, we detail the LMF
method and report on its overall performance.
Results and Discussion
To test the LMF method a 90-gene expression signature was
derived from an unbiased genome-wide transcriptional anal-
ysis of a cell culture model of hematopoietic differentiation.
Total RNA was isolated from HL60 cells following treatment
with tretinoin (all-trans retinoic acid) or vehicle (dimethyl
sulfoxide [DMSO]) alone, amplified and labeled by in vitro
transcription (IVT), and hybridized to Affymetrix GeneChip
microarrays (Affymetrix Inc., Santa Clara, CA, USA). Fea-
tures reporting above threshold were binned into three
groups of equal size on the basis of expression level (low = 20-
60 units; medium = 60-125 units; and high = >125 units). Ten
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transcripts exhibiting low (1.5-2.5×), moderate (3-4.5×), and
high (>5×) differential expression between the two condi-
tions were then selected from each bin, populating a matrix of
nine classes (Additional data file 1), thereby spanning the
range of differential expression likely to be encountered in a
typical signature analysis experiment.
Probe pairs were designed against each of the 90 transcripts
(Additional data file 2) and tested against 10 aliquots of the
tretinoin-treated and vehicle-treated HL60 RNA to provide a
measure of the reproducibility of LMF. Replicate measure-
ments were highly correlated, with 97.9% of data points fall-
ing within twofold of their corresponding means (Figure 2).
Much of the variability was explained by a single transcript,
accounting for 34% of the data points outside this range. The
overall reproducibility of the assay was therefore extremely
high.
We next considered the extent to which LMF could recapitu-
late the gene expression signature discovered with microar-
rays. Estimates of the extent of differential expression
reported by both solutions were very similar, even in the low
Method overview Figure 1
Method overview. Transcripts are captured on immobilized poly-dT and reverse transcribed. Two oligonucleotide probes are designed against each 
transcript of interest. The upstream probes contain 20 nt complementary to a universal primer (T7) site, one of 100 different 24 nt barcode sequences, 
and a 20 nt sequence complementary to the 3'-end of the corresponding first-strand cDNA. The downstream probes are 5'-phosphorylated and contain a 
20 nt sequence contiguous with the gene-specific fragment of the upstream probe and a 20 nt universal primer (T3) site. Probes are annealed to their 
targets, free probes removed, and juxtaposed probes joined by the action of ligase to yield synthetic 104 nt amplification templates. PCR is performed with 
T3 and 5'-biotinylated T7 primers. Biotinylated barcoded amplicons are hybridized against a pool of 100 sets of optically addressed microspheres each 
expressing capture probes complementary to one of the barcodes, and incubated with streptavidin-phycoerythrin to label biotin moieties fluorescently. 
Captured labeled amplicons are quantified and beads decoded by flow cytometry. nt nucleotides.
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basal and low differential expression classes (Figure 3). Five
probe pairs produced gross errors, which is in accordance
with our typical first-pass probe failure rate of 5%. All failures
can generally be remedied by probe redesign. The overall cor-
relation of log ratios between the platforms across all 90 tran-
scripts was 0.924, demonstrating that for the vast majority of
transcripts the LMF method faithfully recovered the micro-
array-defined changes. A repeat of this entire LMF analysis
on two additional occasions yielded similar results. The coef-
ficient of variation of mean expression level for each of the 90
features across all three independent evaluations had a mean
of 13.8% (range 1.1-49.8%) indicating high stability of the
platform.
The most important attribute of a signature analysis technol-
ogy is its ability to discriminate between biologic states. To
test this, we used LMF to collect data for our 90 gene feature
set from 94 microtiter well cultures of HL60 cells each treated
with either tretinoin or vehicle. Approximately 7,500 cell
equivalents were assayed from each well. LMF has been suc-
cessfully applied to the analysis of clinical specimens of as few
as 5,000 cell equivalents (data not shown). A k-nearest-
neighbor (KNN) classification algorithm trained on the origi-
nal 90-gene, microarray-derived expression signature deliv-
ered a classification accuracy of 100% for these samples.
Classifiers built in the space of the nine previously defined
expression classes (10 transcripts each) also had extremely
high accuracy, ranging from 85.2% to 100% (Table 1), indicat-
ing that LMF performs well even for small signatures popu-
lated with nonabundant transcripts and with only modest
differential expression. We note that the classification accu-
racy was high despite the tendency of LMF to underestimate
the extent of differential expression relative to the Affymetrix
platform (Figure 3). Indeed, KNN classifiers built and tested
by leave-one-out cross-validation on positive and negative
control wells from a number of actual small molecule screens
performed with LMF in our laboratory also delivered impres-
sive accuracies (30-gene androgen signature, 642 wells:
98.8% accuracy; 11-gene sarcoma signature, 766 wells: 99.6%
accuracy; 21-gene adipocyte signature, 324 wells: 100% accu-
racy; and 11-gene neuroblastoma signature, 191 wells: 99.5%
accuracy; data not shown). Taken together, these data indi-
cate that LMF represents a highly accurate signature analysis
method that is suitable for high-throughput applications.
LMF makes possible a wide variety of gene expression-based
applications that have the potential to be transforming, par-
ticularly in the area of small molecule screening. High-
throughput small molecule screens based on gene expression
have previously been suggested, but they have been limited to
the measurement of a single gene by either reporter assay or
real-time PCR, or by a small signature of up to five genes
using a mass spectrometric readout [9]. The ability to meas-
ure more complex (up to 100-transcript) signatures (with
concomitant increases in sensitivity and robustness) in high
throughput has not previously been feasible. The LMF
method now makes such signature-based small molecule
screening practical.
LMF should be distinguished from other bead-based mRNA
expression methods. BADGE (Beads Array for the Detection
of Gene Expression) combines IVT labeling with flow cyto-
metric detection [10]. RNA-mediated annealing, selection
and ligation (RASL) and DNA-mediated annealing, selection
and ligation (DASL) are ligation-based methods that rely on
self-assembled fibreoptic bead arrays for detection [11,12].
Although these approaches have demonstrated feasibility, the
labeling costs for IVT approach US$100 (versus about $0.25
for LMF) and the costs of flow-based detection compare very
favorably with those of fibreoptic bead arrays. Even the most
inexpensive custom low-density microarray solutions have
detection costs at least one order of magnitude greater than
that of LMF and they also commonly suffer from high initial
set-up charges. Furthermore, LMF has been implemented in
large-scale, 384-well, plate-based screens, whereas neither
BADGE or RASL/DASL nor existing microarray products are
amenable to a comparable high-throughput implementation
at any cost.
Conclusion
Genome-wide DNA microarray technology continues to be a
mainstay of biologic discovery. However, the ability to meas-
ure gene expression signatures of interest with great rapidity
and flexibility, and at very high throughput and dramatically
lower cost, represents, in our view, the next transformative
technology in the gene expression field. We believe that the
Reproducibility of the method Figure 2
Reproducibility of the method. Mean expression levels for each transcript 
under each condition were computed and the deviation of each individual 
data point from its corresponding mean was recorded. A histogram of the 
fraction of data points in each of 12 bins of fold deviation values is shown. 
This plot represents 1,800 data points (two conditions × 90 transcripts × 
10 replicates).
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LMF method described here has the potential for such
impact.
Materials and methods
Cell culture and RNA isolation
HL60 (human promyelocytic leukemia) cells were cultured in
RPMI supplemented with 10% fetal bovine serum and antibi-
otics. Cells were treated with 1 μmol/l tretinoin (all-trans
retinoic acid; Sigma-Aldrich, St Louis, MO, USA) in dimethyl
sulfoxide (DMSO; final concentration 0.1%) or DMSO alone
for five days. Total RNA was isolated from bulk cultures with
TRIzol Reagent (Invitrogen, Carlsbad, CA, USA), in accord-
ance with the manufacturer's directions. For the classification
exercise, microtiter plate cultures were treated with 200
nmol/l tretinoin or DMSO for two days to mimic the submax-
imal signatures likely to be encountered in a small molecule
screen, and were and prepared for mRNA capture by the addi-
tion of Lysis Buffer (RNAture, Irvine, CA, USA).
Microarrays
Total RNA was amplified and labeled using a modified Eber-
wine method, the resulting cRNA was hybridized to Affyme-
trix GeneChip HG-U133A oligonucleotide microarrays, and
the arrays were scanned in accordance with the manufac-
turer's directions. Raw data were deposited in the National
Center for Biotechnology Information (NCBI) Gene Expres-
sion Omnibus (GEO [13]) and are accessible through GEO
series accession number GSE5007. Intensity values were
scaled such that the overall fluorescence intensity of each
microarray was equivalent. Expression values below an arbi-
trary baseline (20) were set to 20.
Performance in a representative gene space Figure 3
Performance in a representative gene space. Total RNA from HL60 cells treated with tretinoin or vehicle (DMSO) alone were analyzed by LMF in the 
space of 90 transcripts selected from microarray analysis of the same material. Plots depict log ratios of expression levels (tretinoin/DMSO) reported by 
both platforms for each transcript, in each of nine classes. Correlation coefficients of the log ratios between platforms within each class are shown. Yellow 
bars represent microarray findings and green bars LMF findings. Ratios were computed on the means of three parallel hybridizations of the pooled product 
from three amplification and labeling reactions (microarray) or 10 parallel amplification and hybridization procedures (LMF) for each condition. Basal 
expression categories are 20-60 (low), 60-125 (moderate), and >125 (high). Differential expression categories are 1.5-2.5× (low), 3-4.5× (moderate), and 
>5× (high). DMSO, dimethyl sulfoxide.
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Gene selection
The 9,466 probe sets reporting above baseline were first
divided into upregulated and downregulated groups by differ-
ences in mean expression levels between tretinoin and vehicle
treatments. Each of these groups was further divided into
three sets of approximately equal size on the basis of the lower
mean expression level. The selected basal expression catego-
ries were 20-60 (low), 60-125 (moderate), and >125 (high).
Probe sets reporting small (1.5-2.5×), medium (3-4.5×), or
large (>5×) changes in mean expression level within each
basal expression category were extracted and ranked by sig-
nal to noise ratio. The top five probes mapping to unique Ref-
Seq identifiers according to NetAffx [14] in each of the 18
c a t e g o r i e s  w e r e  s e l e c t e d ,  p o p u l a t i n g  n i n e  s e t s  o f  1 0  g e n e s
(Additional data file 1).
Probes and primers
Upstream probes were composed (5' to 3') of the complement
of the T7 primer site (TAA TAC GAC TCA CTA TAG GG), a 24
nucleotide (nt) barcode, and a 20 nt gene-specific sequence.
Downstream probes were 5'-phosphorylated, and contained a
20 nt gene-specific sequence and the T3 primer site (TCC CTT
TAG TGA GGG TTA AT). Barcode sequences were developed
by Tm Bioscience (Toronto, Ontarion, Canada) [15] and
detailed in the Luminex FlexMAP Microspheres Product
Information Sheet [8]. Gene-specific fragments of probes
were designed against the Oligator Human Genome RefSet,
keyed by RefSeq identifier, where available. A 40 nt region
was manually selected from within these 70 nt sequences to
yield two fragments of equal length with roughly similar base
composition and juxtaposing nucleotides being C-G or G-C,
where possible. Probe sequences are provided in Additional
data file 2. Capture probes contained the complement of the
barcode sequences and had 5'-amino modification and a C12
linker. The T7 primer (5'-TAA TAC GAC TCA CTA TAG GG-
3') was 5'-biotinylated. The T3 primer has the sequence 5'-
ATT AAC CCT CAC TAA AGG GA-3'. Oligonucleotides (all
with standard desalting) were from Integrated DNA Technol-
ogies (Coralville, IA, USA).
Beads and bead coupling
Luminex xMAP Multi-Analyte COOH Microspheres [8] were
coupled to capture probes in a semi-automated microtiter
plate format. Approximately 2.5 × 106 microspheres were dis-
pensed to the wells of a V-bottomed microtiter plate, pelleted
by centrifugation at 1800 g for 3 minutes, and the superna-
tant removed. Beads were resuspended in 25 μl binding
buffer (0.1 M 2- [N-morpholino]ethansulfonic acid; pH 4.5)
by sonication and pipeting, and 100 pmol capture probe was
added. A volume of 2.5 μl of a freshly prepared 10 mg/ml
aqueous solution of 1-ethyl-3-(3-dimethylaminopropyl) car-
bodiimide hydrochloride (Pierce, Milwaukee, WI, USA) was
added, and the plate incubated at room temperature in the
dark for 30 minutes. This addition and incubation step was
repeated, and 180 μl 0.02% Tween-20 added with mixing.
Beads were pelleted by centrifugation, as before, and washed
sequentially in 180 μl 0.1% sodium dodecyl sulfate and 180 μl
tris-EDTA (TE) (pH 8.0) with intervening spins. Coupled
microspheres were resuspended in 50 μl TE (pH 8.0) and
stored in the dark at 4°C for up to one month. Bead mixes
were freshly prepared and contained about 1.5 × 105/ml of
each microsphere in 1.5× TMAC buffer (4.5 mol/l tetrameth-
ylammonium chloride, 0.15% N-lauryl sarcosine, 75 mmol/l
tris-HCl [pH 8.0], and 6 mmol/l EDTA [pH 8.0]). The map-
ping of bead number to capture probe sequence is provided in
Additional data file 3.
Ligation-mediated amplification
Transcripts were captured in oligo-dT coated 384 well plates
(GenePlateHT; RNAture) from total RNA (500 ng) in Lysis
Buffer (RNAture) or whole cell lysates (20 μl). Plates were
covered and centrifuged at 500 g for one minute, and incu-
bated at room temperature for one hour. Unbound material
was removed by inverting the plate onto an absorbent towel
and spinning as before. A volume of 5 μl of an M-MLV reverse
transcriptase reaction mix (Promega, Madison, WI, USA)
containing 125 μmol/l of each dNTP (Invitrogen) was added.
The plate was covered, spun as before, and incubated at 37°C
for 90 minutes. Wells were emptied by centrifugation, as
before. A volume of 10 fmol of each probe was added in 1×
Taq Ligase Buffer (New England Biolabs, Ipswich, Ma, USA;
5 μl), the plate covered, spun as before, heated at 95°C for two
minutes and maintained at 50°C for six hours. Unannealed
probes were removed by centrifugation, as before. A volume
of 5 μl of 1× Taq Ligase Buffer containing 2.5 U Taq DNA
ligase (New England Biolabs) was added, the plate covered,
spun as before, and incubated at 45°C for one hour followed
by 65°C for 10 minutes. Wells were emptied by centrifugation,
as before. A volume of 15 μl of a HotStarTaq DNA Polymerase
mix (Qiagen, hilden, Germany) containing 16 μmol/l of each
dNTP (Invitrogen) and 100 nmol/l of T3 primer and bioti-
nylated T7 primer was added. The plate was covered, spun as
before, and polymerase chain reaction performed in a
Thermo Electron (Milford, MA, USA) MBS 384 Satellite
Thermal Cycler (initial denaturation of 92°C for 9 minutes,
92°C for 30 s, 60°C for 30 s, 72°C for 30 s for 39 cycles; final
Table 1
Classification accuracy
Differential expression
1.5-2.5× 3-4.5× >5×
Basal 
expression 
level
20-60 87.5 97.7 97.7
60-125 85.2 98.9 94.3
>125 98.9 98.9 100
Accuracy (%) of a k-nearest-neighbor classifier trained on microarray 
data to predict the true identity (tretinoin or dimethyl sulfoxide) of 88 
test samples in the space of each of the nine gene classes from Figure 3.R61.6 Genome Biology 2006,     Volume 7, Issue 7, Article R61       Peck et al. http://genomebiology.com/2006/7/7/R61
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extension at 72°C for 5 minutes). Total time from the addition
of lysis buffer to hybridization-ready product for 96 samples
processed in parallel in a single microtiter plate is approxi-
mately 14 hours.
Hybridization and detection
A volume of 15 μl of LMA reaction product was mixed with 5
μl TE (pH 8.0) and 30 μl bead mix (about 4,500 of each
microsphere) in the wells of a Thermowell P microtiter plate
(Costar, Corning, NY, USA). The plate was covered and incu-
bated at 95°C for two minutes and maintained at 45°C for 60
minutes. A volume of 20 μl of a reporter mix containing 10
ng/μl streptavidin R-phycoerythrin conjugate (Molecular
P r o b e s ,  E u g e n e ,  O R ,  U S A )  i n  1 ×  T M A C  b u f f e r  ( 3  m o l / l
tetramethylammonium chloride, 0.1% N-lauryl sarcosine, 50
mmol/l tris-HCl [pH 8.0], 4 mmol/l EDTA [pH 8.0]) was
added with mixing and incubation continued at 45°C for five
minutes. Beads were analyzed with a Luminex 100 instru-
ment [8]. Sample volume was set at 50 μl and flow rate was
60 μl/minute. A minimum of 100 events were recorded for
each bead set and median fluorescence intensities (MFIs)
computed. Total time from the start of hybridization to down-
load of raw data from the instrument for 96 samples proc-
essed in parallel in a single microtiter plate is approximately
three hours. Expression values for each transcript were cor-
rected for background signal by subtracting the MFI of corre-
sponding bead sets from blank (TE only) wells. Values below
an arbitrary baseline (5) were set to 5, and all were normal-
ized against an internal control feature (GAPDH_3).
k-Nearest-neighbor classifier
The microarray-derived expression signature from long dura-
tion, high-dose tretinoin or vehicle treatments was used to
train a series of KNN classifiers in the spaces of the full 90-
member gene set and each of the nine 10-member gene cate-
gories. These were applied to the corresponding data from the
88 LMF test samples whose internal reference feature
(GAPDH_3) was within two standard deviations from the
mean. To permit the cross-platform analysis, both the train
and test data sets were normalized so that each gene had a
mean of zero and a standard deviation of one. The KNN algo-
rithm classifies a sample by assigning it the label most fre-
quently represented among the k nearest samples. In this case
k  was set to 3. The votes of the nearest neighbors were
weighted by one minus the cosine distance. This analysis was
performed with the GenePattern software package [16].
Additional data files
The following additional data are included with the online
version of this article: An Excel file listing the genes populat-
ing the representative gene space (Additional data file 1); an
Excel file containing the LMF probe sequences (Additional
data file 2); an Excel file providing a mapping of bead number
to capture probe sequence (Additional data file 3); a docu-
ment containing the Affymetrix data used to select the repre-
sentative gene space (in the tab-delimited .res file format;
Additional File 4); a document containing raw LMF data used
to assess the reproducibility of the method and for compari-
sons between platforms (in the tab-delimited .txt file format;
Additional data file 5); a document containing raw LMF data
used to assess the stability of the LMF method (in the tab-
delimited .txt file format; Additional data file 6); a document
containing raw LMF data used to assess the stability of the
LMF method (in the tab-delimited .txt file format; Additional
data file 7); and a document containing raw LMF data from
the analysis of the microtiter cultures, which were used in the
classification exercise (in the tab-delimited .txt file format;
Additional data file 8).
Additional data file 1 The genes populating the representative gene space The genes populating the representative gene space Click here for file Additional data file 2 The LMF probe sequences The LMF probe sequences Click here for file Additional data file 3 A mapping of bead number to capture probe sequence A mapping of bead number to capture probe sequence Click here for file Additional data file 4 A document containing the Affymetrix data used to select the rep- resentative gene space A document containing the Affymetrix data used to select the rep- resentative gene space Click here for file Additional data file 5 A document containing raw LMF data used to assess the reproduc- ibility of the method and for comparisons between platforms A document containing raw LMF data used to assess the reproduc- ibility of the method and for comparisons between platforms Click here for file Additional data file 6 A document containing raw LMF data used to assess the stability of  the LMF method A document containing raw LMF data used to assess the stability of  the LMF method Click here for file Additional data file 7 A document containing raw LMF data used to assess the stability of  the LMF method A document containing raw LMF data used to assess the stability of  the LMF method Click here for file Additional data file 8 A document containing raw LMF data from the analysis of the  microtiter cultures, which were used in the classification exercise A document containing raw LMF data from the analysis of the  microtiter cultures, which were used in the classification exercise Click here for file
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